SinoMab BioScience Balance Sheet Health
Financial Health criteria checks 2/6
SinoMab BioScience has a total shareholder equity of CN¥295.6M and total debt of CN¥391.4M, which brings its debt-to-equity ratio to 132.4%. Its total assets and total liabilities are CN¥847.8M and CN¥552.2M respectively.
Key information
132.4%
Debt to equity ratio
CN¥391.40m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥234.66m |
| Equity | CN¥295.58m |
| Total liabilities | CN¥552.20m |
| Total assets | CN¥847.79m |
Recent financial health updates
No updates
Recent updates
Update: SinoMab BioScience (HKG:3681) Stock Gained 21% In The Last Year
Mar 04
What You Need To Know About SinoMab BioScience Limited's (HKG:3681) Investor Composition
Jan 28Did SinoMab BioScience Limited (HKG:3681) Insiders Buy Up More Shares?
Jan 01
Loss-Making SinoMab BioScience Limited (HKG:3681) Expected To Breakeven In The Medium-Term
Nov 30Financial Position Analysis
Short Term Liabilities: 3681's short term assets (CN¥270.2M) exceed its short term liabilities (CN¥172.6M).
Long Term Liabilities: 3681's short term assets (CN¥270.2M) do not cover its long term liabilities (CN¥379.6M).
Debt to Equity History and Analysis
Debt Level: 3681's net debt to equity ratio (53%) is considered high.
Reducing Debt: 3681's debt to equity ratio has increased from 36.5% to 132.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 3681 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 3681 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.5% each year